Intelligent Bio Solutions has struck a major manufacturing partnership with global MedTech heavyweight Syrma Johari MedTech Ltd, a move set to dramatically cut production costs, boost margins, and accelerate the company’s push toward the US market.

 

The strategic deal expands Intelligent Bio Solutions’ (INBS) global manufacturing capacity and strengthens supply-chain resilience as the company scales production of its Intelligent Fingerprinting Drug Screening Reader. The partnership is expected to drive annual production cost savings of more than 40 per cent and lift gross margins by approximately 20 percentage points ahead of a planned US market entry in 2026.

 

Syrma Johari’s manufacturing capacity is around four times INBS’ current output, positioning the company to meet rising global demand as commercial operations expand. The agreement also reduces reliance on a single supplier, improving continuity and flexibility across multiple regions.

 

With more than 45 years of experience, Syrma Johari is a globally recognised medical device engineering and manufacturing organisation, operating 14 facilities and four design and innovation centres across India, Europe and the United States.

 

The company’s vertically integrated, export-focused operating model delivers efficiencies across sourcing, tooling, testing and logistics. Its expertise in electronics, mechanical assembly, PCB manufacturing, functional testing and clean-room processes positions it to produce INBS’ fingerprint drug-screening reader at scale while maintaining consistent quality and lowering costs over time.

 

Syrma Johari is also preparing to open a new medical-grade plastics manufacturing facility in India in January 2026, further expanding its capabilities and strengthening its role as a reliable manufacturing hub for global MedTech companies.

 

The partnership also supports INBS’ regulatory and commercial ambitions, with Syrma Johari providing end-to-end quality systems and regulatory documentation across major jurisdictions, including the US, Europe, the UK, Canada and Asia-Pacific markets.

 

“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, vice president of global quality and operations at Intelligent Bio Solutions. 

 

“Its global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our Drug Screening Reader. This collaboration strengthens our supply chain, supports future growth, and enhances our ability to deliver reliable, high-quality products to customers around the world.”

 

Syrma Johari’s leadership said the partnership reflects a strong alignment in innovation, quality and long-term vision, and positions both companies to scale a disruptive drug-screening technology globally.

 

“Partnering with Intelligent Bio Solutions is an exciting opportunity to apply our engineering strength, manufacturing scale, and quality systems to a breakthrough technology with global potential,” said Pankaj Wadke, head international sales & business development at Syrma Johari MedTech Ltd. 

 

“At Syrma Johari MedTech, we are committed to enabling innovative solutions that make a meaningful impact, and we look forward to supporting INBS as they expand access to this disruptive, non-invasive drug-screening platform.”